MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, December 6, 2014

CME program: Targeting New Treatment Pathways for Multiple Sclerosis

Shifting the Paradigm in Multiple Sclerosis Treatment by Targeting New Pathways

Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks and destroys myelin and myelinated axons in the CNS and is the most common nontraumatic cause of neurological disability, morbidity, and impairment in young adults. Approximately 400,000 Americans and over 2.5 million people worldwide are affected by MS. 

Proper staging and assessment of progression are critical to making appropriate decisions in determining clinical strategies. For clinicians who manage patients with MS, it is important to keep up to date with the latest treatment advances, their benefits, limitations, and optimal use so that they can provide the best outcomes for their patients.

 Treatments are now being designed that target the B-cell, and these targeted approaches may match or surpass current treatment modalities in terms of efficacy, while also reducing the risk of adverse effects. In this program, leading clinicians and researchers will discuss the latest thinking on approaches to monitoring progression and the latest data regarding targeted therapies that may improve clinical outcomes for patients with MS.



CREDITS         LEARN More of this event

Provider Statement: This continuing medical education activity is provided by 
Support Statement: This activity is supported by an educational grant from Genentech, Inc.

 Keep CURRENT with MS Views and News - OPT-IN here


No comments: